Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $143.48 USD
Change Today +1.02 / 0.72%
Volume 30.0K
TARO On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 2:12 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

taro pharmaceutical indus (TARO) Snapshot

Open
$141.34
Previous Close
$142.46
Day High
$144.29
Day Low
$139.01
52 Week High
02/6/15 - $173.00
52 Week Low
08/8/14 - $130.45
Market Cap
6.1B
Average Volume 10 Days
63.3K
EPS TTM
$11.26
Shares Outstanding
42.8M
EX-Date
--
P/E TM
12.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for TARO PHARMACEUTICAL INDUS (TARO)

taro pharmaceutical indus (TARO) Related Businessweek News

No Related Businessweek News Found

taro pharmaceutical indus (TARO) Details

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It sells and distributes its products principally to drug industry wholesalers, drug store chains, and mass merchandisers, as well as to healthcare institutions, drug store chains, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

1,339 Employees
Last Reported Date: 07/1/15
Founded in 1959

taro pharmaceutical indus (TARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taro pharmaceutical indus (TARO) Key Developments

Taro Pharmaceutical Industries Ltd. Reports Sales Results for the Year 2015

Taro Pharmaceutical Industries Ltd. reported sales results for the year 2015. For the year, the company reported total sales of $863 million, of which the US contributed $777 million. US sales increased by $107.7 million or 16.1% year on year, of which $97.2 million came from price increases in 12 generic products.

Taro Pharmaceutical Industries Seeks Acquisitions

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) is seeking acquisitions. Kal Sundaram, Chief Executive Officer, said, "We continue our business development efforts to seek growth opportunities, whether it is through organic growth, acquisition, or strategic alliances such as goal promotion or core development opportunities. However, we remain disciplined in our evaluation of all these opportunities to ensure we are creating long-term shareholder value. We continue to manage our costs and driving operating efficiencies in the organization."

Taro Pharmaceutical Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Taro Pharmaceutical announced unaudited consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company reported net sales of $244,180,000 against $187,176,000 a year ago. Operating income was $153,541,000 against $101,544,000 a year ago. Income before income taxes was $189,504,000 against $107,089,000 a year ago. Income from continuing operations was $152,632,000 or $3.56 per basic and diluted share against $89,656,000 or $2.10 per basic and diluted share a year ago. Net income attributable to the company was $152,292,000 or $3.56 per basic and diluted share against $89,640,000 or $2.10 per basic and diluted share a year ago. Net income was positively impacted by foreign exchange (FX) income of $32.5 million, compared to $3.9 million, the result of favorable currency fluctuations. For the year, the company reported net sales of $862,944,000 against $759,285,000 a year ago. Operating income was $527,631,000 against $430,253,000 a year ago. Income before income taxes was $581,680,000 against $443,907,000 a year ago. Income from continuing operations was $485,621,000 or $11.32 per basic and diluted share against $361,178,000 or $8.15 per basic and diluted share a year ago. Net income attributable to the company was $484,257,000 or $11.31 per basic and diluted share against $360,387,000 or $8.14 per basic and diluted share a year ago. Net cash provided by operating activities was $406,788,000 against $357,644,000 a year ago. Purchase of plant, property and equipment was $19,997,000 against $21,249,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TARO:US $143.48 USD +1.02

TARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.39 USD +0.02
Dr Reddy's Laboratories Ltd 3,717 INR +128.95
Glenmark Pharmaceuticals Ltd 1,019 INR -0.25
IGI Laboratories Inc $6.38 USD +0.05
Impax Laboratories Inc $47.35 USD +1.04
View Industry Companies
 

Industry Analysis

TARO

Industry Average

Valuation TARO Industry Range
Price/Earnings 12.6x
Price/Sales 7.1x
Price/Book 4.3x
Price/Cash Flow 12.6x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARO PHARMACEUTICAL INDUS, please visit www.taro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.